Shares of Retractable Technologies, Inc. (RVP Quick QuoteRVP - Free Report) have lost 3.1% since the company reported its earnings for the quarter ended Dec. 31, 2025, against a 0.9% rise in the S&P 500 Index over the same period. Over the past month, however, the stock edged up 2.9%, outperforming the broader market’s 5.2% decline.

Retractable Technologies’ Earnings Snapshot

Retractable Technologies reported full-year 2025 revenues of $38.3 million, representing a 15.8% increase from $33 million in 2024. This growth was driven by higher domestic sales, which rose 9.7% and a 64% increase in international revenues, primarily due to stronger EasyPoint needle demand.

Despite top-line growth, profitability remained under pressure. RVP posted a net loss of $12.6 million in 2025, slightly wider than the $11.9 million loss reported in 2024. On a per-share basis, diluted loss stood at $0.43 compared with $0.40 a year earlier. Gross profit improved to $47,046 from a loss of $1 million in the prior year, reflecting higher volumes but still constrained margins. Gross margins improved modestly to 0.1% from negative 3.1% in 2024, indicating slight operational improvement despite ongoing cost headwinds.

RVP’s Revenue Mix and Cost Pressures

Retractable Technologies’ revenue composition highlights continued reliance on core syringe products, which accounted for 65.1% of sales in 2025, while EasyPoint products contributed 31.2%. Domestic markets remained dominant, representing 84.2% of total revenues, though international growth outpaced domestic expansion.

Cost pressures persisted, with the cost of manufactured product rising 12.7% from 2024. Tariff expenses alone totaled approximately $1.8 million in 2025, contributing to the elevated cost of goods sold and limiting margin expansion. Operating expenses increased 5.7%, partly due to higher sales and marketing costs and an impairment charge of about $954,000.

Quarterly data further illustrates margin volatility. For the quarter ended Dec. 31, 2025, sales were $9.4 million compared with $9.1 million in the year-ago period, but RVP recorded a net loss of $2.4 million against a net income of $3.8 million a year earlier. Diluted loss per share for the December 2025 quarter was $0.09 with against diluted earnings per share of $0.14 in the year-ago quarter.

Factors Influencing Retractable Technologies’ Performance

A key factor shaping results is the evolving tariff environment. Retractable Technologies sourced 62.6% of its products from China in 2025, exposing it to tariffs as high as 120% on certain syringe and needle imports. These tariffs have materially increased production costs and introduced uncertainty around future pricing and supply chain strategies.

Additionally, lingering inventory overhang from pandemic-era vaccine demand has dampened domestic purchasing activity. Management noted that customers may still hold excess inventory, suppressing near-term demand visibility.

RVP’s Management Commentary and Strategic Response

Management emphasized efforts to mitigate tariff impacts by shifting production toward domestic manufacturing. Investments in facility expansion and equipment upgrades — partly funded by a government agreement — are intended to reduce reliance on imports and improve long-term cost competitiveness.

However, these initiatives have increased overhead and near-term expenses. Retractable Technologies also implemented workforce reductions during 2025 to offset rising costs. Management expects tariffs to continue exerting a material influence on operations and financial performance going forward.

Retractable Technologies’ Liquidity and Balance Sheet

Retractable Technologies ended 2025 with $2.6 million in cash and $34.4 million invested in debt and equity securities. Operating cash flow remained negative, with $7.1 million used in operations during the year, primarily due to ongoing losses.

Despite these pressures, management believes existing cash and investment holdings will support near-term operational needs. However, liquidity is expected to decline over the next one to three years due to higher costs and capital requirements.

RVP’s Guidance and Outlook

RVP did not provide explicit financial guidance. However, management expects tariffs to continue having a material impact on operations and financial performance. Ongoing efforts to expand domestic manufacturing capacity and improve efficiency are expected to play a key role in mitigating these pressures over time.

Near-term margins are likely to remain under pressure as Retractable Technologies absorbs higher production costs and navigates uncertain demand patterns. Management also highlighted uncertainty surrounding future tariff policies and international order timing, which could affect revenue visibility.

Retractable Technologies’ Other Developments

Retractable Technologies incurred approximately $1.8 million in tariff-related expenses in 2025 and continues to adapt its supply chain and production footprint in response to trade policy changes. It also recorded a $1.9 million litigation settlement gain during the year, providing some offset to operating losses.

No major acquisitions, divestitures or restructuring transactions were reported during the period.